
Cancer- Related Bleeding and Thrombosis

Anjlee Mahajan, MD

Assistant Professor

University of California, Davis



A 55 year old woman presents after recent diagnosis of metastatic lung adenocarinoma. She is concerned as her friend had pancreatic cancer and died from a pulmonary embolism.

She asks what her risk of having a pulmonary embolism and if there is anything that can be done to prevent this?

The Epidemiology of Cancer Associated Thrombosis


- Cancer accounts for nearly 20% of all VTE cases (1)
- The risk of VTE in cancer patients is is ~5x greater than noncancer controls (2)
- Cancer is a known predictor of mortality in those with VTE (3)


1. Heit JA, et al. Arch Intern Med 2002; 162: 1245–1248.


2. Cronin-Fenton et al. Br J Cancer 2010, 103 947-953


3. Braeken et al. Am J Empidemiology 2010, 171 (p 11069-1115)

Gender adjusted Hazard ratios of death in participants with and without cancer (The Tromso study 1994-2007)










Chew et al. Arch Intern Med, 2006, 166, 458-464




For metastatic lung cancer the 1 year cumulative incidence of VTE is 7%.

Khorana Score


Patient Characteristic	Risk Score
 Site of Primary Cancer ➤ Very High Risk (stomach, pancreas) ➤ High Risk (lung, lymphoma, gynecologic, bladder, testicular) 	2 1
Prechemotherapy platelet count ≥ 350 x 10 ⁹ /L	1
Hgb < 10 g/dL	1
Prechemotherapy leukocyte count ≥ 11 × 10 ⁹ /L	1
BMI 35 kg/m ²	1

Total Score 0 1-2 3 or higher Risk of Symptomatic VTE Low (0.8-3%) Intermediate (1.8-8.4%) High (7.1-41%)



VTE PROPHYLAXIS FOLLOWING DISCHARGE AND FOR AMBULATORY CANCER PATIENTS AT RISK^a

AT-RISK POPULATION






ORIGINAL ARTICLE

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

- Double blind randomized trial of high risk ambulatory cancer patients (Khorana score <u>></u>2) assigned to prophylactic rivaroxaban 10mg daily for 180 days
 - All underwent screening ultrasound prior to enrollment
- VTE occurred in 6% of rivaroxaban group vs 8.8% placebo group (HR 0.66, 95% CI 0.1-1.09, p=0.10)
- Major bleeding occurred in 2% of rivaroxaban group vs 1% in placebo group (HR 1.96; 95% CI 0.59-6.49)
- VTE prophylaxis with rivaroxaban did not significant lower incidence of VTE or death due to VTE in follow up







The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

- Randomized, placebo controlled, study of apixaban 2.5mg BID for thromboprophylaxis in ambulatory cancer patients for 180 days
 - Also used Khorana score of >2
 - Did not perform baseline ultrasound prior to enrollment to exclude those with VTE
- VTE in 4.2% of those in apixaban group and 10.2% in placebo group (HR 0.41, 95% CI 0.26-0.65, p<0.001)
- Major Bleeding occurred in 3.5% of those in apixaban group vs 1.8% in placebo (HR 2; 95% CI 1.01-3.95; p=0.046)





Outcome	CASSINI Trial		AVERT Trial		Cumulative Values					
	Rivaroxaban	Placebo	Apixaban	Placebo	DOACs	Placebo	Relative Risk (95% CI)	Absolute Difference	No. Needed to Treat or Harm†	
			number/total	number (percent))			percentage points		
Primary efficacy outcome										
ITT analysis	25/420 (6.0)	37/421 (8.8)	12/288 (4.2)	28/275 (10.2)	37/708 (5.2)	65/696 (9.3)	0.56 (0.38–0.83)	-4.1	24	
Analysis during treatment period	11/420 (2.6)	27/421 (6.4)	3/288 (1.0)	20/275 (7.3)	14/708 (2.0)	47/696 (6.8)	0.29 (0.16–0.53)	-4.8	21	
Symptomatic VTE: ITT analysis	15/420 (3.6)	19/421 (4.5)	9/288 (3.1)	22/275 (8.0)	24/708 (3.4)	41/696 (5.9)	0.58 (0.35–0.94)	-2.5	40	
Major bleeding	8/405 (2.0)	4/404 (1.0)	10/288 (3.5)	5/275 (1.8)	18/693 (2.6)	9/679 (1.3)	1.96 (0.88–4.33)	1.3	77	
Death from any cause	84/420 (20.0)	100/421 (23.8)	35/288 (12.2)	27/275 (9.8)	119/708 (16.8)	127/696 (18.2)	0.92 (0.73-1.16)	-1.4	71	


* In the AVERT trial, the modified intention-to-treat analysis was the primary analysis (574 patients underwent randomization). DOACs denotes direct oral anticoagulants, ITT intention to treat, and VTE venous thromboembolism.

† The number needed to treat is shown for all outcomes except major bleeding (number needed to harm).

Criticisms of CASSINI and AVERT

- The most common cancers (colorectal, breast, prostate) were underrepresented
- Khorana score has been shown to perform poorly in some cancers and does not account for chemotherapy regimen
- Percentage of patients discontinued trial regimen prematurely was high (up to nearly 50%)

"For patients with cancer predicted to be a high risk of VTE based on the Khorana score, none were prescribed anticoagulation without another clinical indication, demonstrating primary prophylaxis is virtually never used."



1. How often do you	Never	Rarely	Sometimes	Usually	Always
Use risk scores to identify patients at high risk of VTE?	58%	29%	8%	4%	0%
Talk to your patients with cancer about the risk of blood clots?	0%	29%	29%	38%	4%
2. How familiar are yo	u with	Not at all	A little bit	Somewhat	Quite a bit
ISTH recommendations for VTE risk assessment and primary prophylaxis?		67%	21%	8%	4%
The Khorana score?		67%	17%	13%	4%

The patient develops a new segmental pulmonary embolism while receiving her second cycle of chemotherapy.

She is initially given low molecular weight heparin but hates giving herself injections and would like to know about alternative therapies.



Treatment of CAT- an Evolution or Revolution?



Hokusai : Edoxaban vs. Dalteparin

- Open label, randomized, noninferiority trial comparing LMWH for 5 days followed by edoxaban 60mg daily vs. Dalteparin
 - Excluded patients with CrCl>95 ml/min
- Recurrent VTE 7.9% Edoxaban vs. 11.3% Dalteparin (HR 0.71; 95% CI 0.42-1.06, p=0.09)
- Edoxaban associated with higher absolute rate of major bleeding vs. Dalteparin (6.9% vs. 4.0%, HR .77; 95% Cl 1.03-3.04, p=0.04)

• *Patients with GI malignancy were more likely to have increase in risk of bleeding with edoxaban vs dalteparin (3.8% vs 1.1%, p=0.02)

SELECT- D: Rivaroxaban vs Dalteparin


- Open label, randomized trial rivaroxaban
 20mg daily vs. Dalteparin
- 6 month cumulative VTE recurrence 4% rivaroxaban vs. 11% Dalteparin (HR 0.43, 95% CI 0.19-0.99)
- Major bleeding was 6% for rivaroxaban vs.
 4% Dalteparin (HR 1.83; 95% CI 0.68-4.96)

*Numerically higher rate of CRNM bleeding in rivaroxaban (13% versus 4%; Most bleeding events – GI bleeds)

CARAVAGGIO: Apixaban vs Dalteparin

- Open label, randomized trial of apixaban 5mg BID daily vs. Dalteparin
- Recurrent VTE rate 5.6% Apixaban vs. 7.9%
 Dalteparin (HR 0.63; 95% CI 0.37-1.07, p<0.001)
- Major bleeding 3.8% in Apixaban vs. 4%
 Dalteparin (HR 0.82; 955 Cl 0.4-1.69, p=0.60)

*GIB not studied as primary endpoint (and few pts with UGI and hematologic malignancy) *Excluded those with brain malignancy and metastases



Risk of major bleeding was significantly elevated in patients with GI cancer treated with DOACs compared to LMWHs (9.3% vs 4.0%; RR, 2.30 [95% CI, 1.08-4.88]; P = .031; $I^2 = 0.0\%$).

Subgroup: GI Cancer

Major bleeding


Study						RR (95% CI)	DOAC Events/Total	LMWH Events/Total	Weight (%)
GI Cancer					_				
Hokusai VTE Cancer SELECT-D				1	*	3.18 (1.08, 9.37) 1.68 (0.59, 4.82)	15/165 9/92	4/140 5/86	22.84 24.01
Subtotal						2.30 (1.08, 4.88)	24/257	9/226	46.85
non-GI Cancer									
Hokusai VTE Cancer				•		1.16 (0.55, 2.43)	14/357	13/384	48.48
SELECT-D				•			2/111	1/117	4.67
Subtotal						1.22 (0.60, 2.48)	16/468	14/501	53.15
Overall ($I^2 = 0.0\%$)			-		-	1.64 (0.98, 2.75)	40/725	23/727	100.00
	.1	.2	.5 1	2	5	10			
		Lower Risk with D	OAC	Lower F	Risk with LMWH				

Take Home Points

- DOACs may cause increased GI bleeding in those with upper GI cancer and possible increase in GU bleeding as well
- Meta-analysis shows possible decrease in recurrent VTE for those treated with DOACs
- General lack of patients with brain malignancy and metastatic brain lesions in these trials
- Beware of drug interactions
 - P-glycoprotein or CYP3A4 inhibitors were excluded on trial and few were receiving checkpoint inhibitors

She is treated with Apixaban 5mg BID for 3 months. She then presents with confusion and MRI shows metastatic disease

She is referred for radiation therapy




Limited Data on Anticoagulation with Intracranial Metastases

- Matched, retrospective cohort study of 293 cancer patients with brain metastases
- 104 with therapeutic enoxaparin and 189 controls
- 12 month Cumulative incidence of ICH at 1 year in enoxaparin group 19% vs 21% in control group (p=0.97, HR 1.02)



ICH with DOACs in patients with brain tumors

- Retrospective cohort study including 172 brain tumor patients (primary and brain metastases)
- In the brain metastases cohort the 12 month Cl of ICH was 27.8% vs 52.9%, (p=0.15) and major ICH was 11.1% vs 17.8% (p=0.38)
- No deaths of ICH in either cohort



IN SUMMARY

- DOACs may be considered in primary prophylaxis in cancer patients
 - Need better predictive models of CAT to assess benefit
 - Longer follow up is also needed
- Use of DOACs in treating CAT has become standard of care
 - Increased risk of GI and GU bleeding in those with upper GI or intraluminal GU malignancy
 - Drug interactions
 - Most data was prior to use of immunotherapy
- More data is needed (including randomized trials) to evaluate use of DOACs in patients with CNS malignancy but preliminary data suggests it is non inferior to LMWH